pipette
ENEnglish

HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α

N. Yamamoto, S. Dobersch, T. M. Robertson, J. H. Sim, A. Wallace-Povirk, N. Chew, A. E. Orellana, J. Aggrey-Fynn, L. Boila, A. Schutter, I. M. Loveless, G. H. Jang, S. Avanessian, G. L. Beatty, S. R. Hingorani, C. Rydberg Millrud, N. G. Steele, D. Barbosa Vendramini Costa, R. Francescone, H. C. Crawford, F. Notta, K. Barry, S. Kugel

PreprintUso en el mundo real

En palabras de los autores

The basal-like subtype of pancreatic ductal adenocarcinoma (PDAC) is associated with poor outcomes and increased chemoresistance. Expression of high mobility group AT-hook 2 (HMGA2), a chromatin architectural protein, marks basal PDAC cells and associates with specific features of the tumor microenvironment (TME), including more immunosuppressive cancer associated fibroblasts (CAFs) and fewer cytotoxic CD8+ T cells. Expression of HMGA2 by tumor cells leads to upregulation of the immunosuppressive markers interleukin 6 (IL6) and leucine-rich repeat containing protein 15 (LRRC15) in associated fibroblasts. Mechanistically, HMGA2 in the tumor cell binds the interleukin 1 alpha (IL1) promoter and upregulates transcription, increasing IL1 in the TME, in turn inducing immunosuppressive fibroblast polarization, increasing regulatory T cells, and decreasing CD8+ T cells. Blockade of the IL1 signaling axis disrupts this tumor-driven microenvironment phenotype and combines with inhibitors of oncogenic KRAS to improve tumor control.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 7 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.02.754697